NCT07123519View on ClinicalTrials.gov

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 13, 2025

Primary Completion Date

August 13, 2026

Study Completion Date

August 13, 2027

Conditions
Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Sjogren's Syndrome (SS)Inflammatory MyopathyAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisAntiphospholipid Syndrome (APS)
Interventions
DRUG

YTS109 cell

Subjects will receive a single infusion of YTS109 cells. The dose groups are set to commence at 3E6 STAR-T cells/kg, employing a 3+3 escalation principle for dose titration.

Trial Locations (1)

Unknown

Institute of Hematology & Blood Diseases Hospital, China, Tianjin

All Listed Sponsors
collaborator

Institute of Hematology & Blood Diseases Hospital, China

OTHER

lead

China Immunotech (Beijing) Biotechnology Co., Ltd.

INDUSTRY